Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-07-02
2003-02-04
Wehbe, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024100, C536S024500, C435S320100
Reexamination Certificate
active
06514948
ABSTRACT:
Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention pertains.
TECHNICAL FIELD OF THE INVENTION
The invention relates to a method for enhancing an immune response by administering an immunostimulatory nucleotide sequence prior to antigen exposure. More particularly, the method is suited for enhancing antibody production, IFN&ggr; release, CTL activity and Th1-related effects in response to antigen administration.
BACKGROUND OF THE INVENTION
Adjuvants are typically administered in conjunction with antigen in vaccination protocols. Adjuvants serve to amplify or modulate the immune response to a co-delivered antigen. Currently, few adjuvants (e.g., alum and MF59) have been approved for use in human vaccination.
Immunostimulatory DNA sequences (ISS) delivered in conjunction with an antigen activate innate immunity and bias the adaptive immune response toward Th1 differentiation. ISS have been used as an adjuvant to amplify the immune response to a co-delivered antigen. See, for example, WO 98/16247, and U.S. Pat. No. 5,736,524 and No. 5,780,448.
There remains a need for optimization of the nature and efficacy of vaccination and immunotherapeutic protocols.
SUMMARY OF THE INVENTION
The invention provides a method for enhancing an immune response to a substance, such as an antigen administered to a subject, or a pathogen to which the subject is exposed. The method can be used to modulate the magnitude, the duration, and the nature of the immune response to subsequent exposure to a substance. The method comprises administering an immunostimulatory nucleotide sequence (ISS) to the subject at least one hour prior to exposure to the substance by the subject. This “pre-priming” of the subject with ISS prior to antigen administration or pathogen exposure results in amplification of the Th1 immune response to the substance as compared to co-administration of ISS and antigen. Pre-priming with ISS also shifts the nature of the immune response from a Th2 type response to a Th1 type response.
Examples of an immune response that can be enhanced by the method of the invention include, but are not limited to, activation of innate immunity (e.g., macrophages, natural killer (NK) cells), a Th1 response, a cytotoxic T lymphocyte (CTL) response, and production of an antibody. The antibody response is preferably increased production of antibodies of the IgG2a subclass. The method can be used for immunizing a subject against an antigen, and provides more effective immunization than if the ISS were co-administered with the antigen. The method can be used prophylactically or therapeutically.
In preferred embodiments, the ISS comprises a CG, p(GC) or p(IC) DNA or RNA nucleotide sequence. Of these, a CG containing nucleotide sequence is preferred. Preferably, the ISS further comprises a pG nucleotide sequence. Examples of an ISS include, but are not limited to, sequences comprising 5′-rrcgyy-3′ (SEQ ID NO: 1), such as AACGTT, AGCGTC, AGCGTT, GACGTT, GGCGTT, AACGTC, and AGCGTC (SEQ ID NOs: 5-11, respectively), 5′-rycgyy-3′ (SEQ ID NO: 2) such as GTCGTT (SEQ ID NO: 24), 5′-rrcgyycg-3′ (SEQ ID NO: 3), or 5′-rycgyycg-3′ (SEQ ID NO: 4).
The ISS is preferably administered between about 6 hours and about 6 weeks prior to antigen administration, and more preferably between about 1 day and about 4 weeks prior to antigen administration. Most preferably, the ISS is administered between about 3 days and about 8 days prior to antigen administration. In a preferred embodiment of the method, the ISS is administered via a systemic route such as a dermal or intramuscular route, or via a mucosal route such as an intranasal, ophthalmic, intrarectal, intravaginal or intratracheal route.
Because pre-priming activates innate immunity, the method of the invention can be used to protect against subsequent infection by a pathogen, such as a viral, bacterial, parasitic or other infectious agent. Preferably, the substance is a pathogen or an antigen associated with an infectious disease, an allergen or a cancer. Examples of infectious disease include, but are not limited to, viral, bacterial, mycobacterial and parasitic disease.
REFERENCES:
patent: 5679647 (1997-10-01), Carson et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5780448 (1998-07-01), Davis
patent: 5849719 (1998-12-01), Carson et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: WO 98/16247 (1998-04-01), None
patent: WO 99/11275 (1999-03-01), None
Threadgill et al. Vaccine. 16(1):76-82, 1998.*
Ott et al. MF59, Chapter 10, Vaccine Design: The Subunit and Adjuvant Approach, Plenum Press, NY, 1995.*
Elkins, et al., “Bacterial DNA Containing CpG Motifs Stimulates Lymphocytes-Dependent Protection if Mice Against Lethal Infection with Intracellular Bacteria,”The Journal of Immunology, (Feb. 1999) 162:2291-2298.
Kreig, et al., “CpG DNA Induces Sustained IL-12 Expression In Vivo and Resistance to Listeria monocytogenes Challenge,”The Journal of Immunology, (1998) 161:2428-2434.
Oxenius, et al., “CpG-Containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines,”Journal of Virology, (May 1999) 73(5):4120-4126.
Martin-Orozco, E. et al. “Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences.”International Immunology, Mar. 1999, vol. 11 No. 7. pp. 1111-1118.
Kobayashi, et al., “Immunostimulatory DNA Prpeiming: A Novel Approach for Prolonged Th-1 biased Immunity,”Cellular Immunology(Nov. 25, 1999) 198(1):69-75.
Spiegleberg, et al., “Inhibition of Allergic Inflammation in the Lung by Plasmid DNA Allergen Immunization,”Pediatric Pulmonology(1999) 18:118-121.
David Broide et al., “Immunostimulatory DNA Sequences Inhibit IL-5, Eosinophilic Inflammation, and Airway Hypterresponsiveness in Mice”,The Journal of Immunology, 1998, pp. 7054-7062.
David Broide et al, DNA-Based Immunization for Asthma,Int'l. Archives of Allergy and Immunology, 1999: 118:453-456.
Anthony A. Horner et al., “Rapid Communication: Immunostimulatory DNA is a Potent Mucosal Adjuvant”,Cellular Immunology, 1998: 190:77-82 (Article No. CI981400).
Arthur M. Krieg et al., “CpG Motifs in Baterial DNA Trigger Direct B-Cell Activation”,Letters to Nature, Apr. 6, 1995, vol. 374, Issue No. 6522, 546-549.
Dennis Klinman et al., “Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines”,Journal of Immunology, Apr. 15, 1997, 158(8):3635-3639.
Claude Leclerc et al., “The Preferential Induction of a Th1 Immune Response by DNA-based Immunization is Mediated by the Immunostimulatory Effect of Plasmid DNA”,Cell Immunol., Aug. 1, 1997, 179(2):97-106.
H.X. Lin et al., “A New Immunostimulatory Complex (PICKCa) in Experimental Rabies: Antiviral and Adjuvant Effects”,Archives of Virology, 1993, 131: 307-319.
Mark Roman et al., “Immunostimulatory DNA Sequences Function as T Helper-1-Promoting Adjuvants”,Nature Medicine, Aug. 1997:3:(8): 849-854.
H.L. Spiegelberg et al., “Inhibition of IgE Formation and Allergic Inflammation by Allergen Gene Immunization and by CpG Motif Immunostimulatory Oligodeoxynucleotides”,Allergy, 1997:53:93-97.
Kobayashi Hiroko
Raz Eyal R.
Borden Paula A.
Bozicevic Field & Francis LLP
Francis Carol L.
Li Janice
The Regents of the University of California
LandOfFree
Method for enhancing an immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for enhancing an immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for enhancing an immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3149693